LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Inicio・Lista de Acciones・Lisata Therapeutics

L
Lisata Therapeutics

Cerrado

1.99 1.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.99

Máximo

2.1

Métricas clave
By Trading Economics
Empleados	26

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-5.3M 15M
Apertura anterior	0.97
Cierre anterior	1.99

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 nov 2025, 16:49 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Adquisiciones, fusiones, absorciones

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Charlas de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Charlas de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Adquisiciones, fusiones, absorciones

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Charlas de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Charlas de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Charlas de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Charlas de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Charlas de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Charlas de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Ganancias

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Ganancias

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Ganancias

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Ganancias

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Ganancias

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Ganancias

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Ganancias

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q EPS MYR0.0079

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Lisata Therapeutics Dist en los últimos 3 meses.

Finanzas

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.